Ocugen Inc
(MEX:OCGN)
MXN
23.06
0 (0%)
Market Cap: 6.85 Bil
Enterprise Value: 6.67 Bil
PE Ratio: 0
PB Ratio: 18.18
GF Score: 33/100 Ocugen Inc at ROTH Conference Transcript
Mar 13, 2023 / 04:00PM GMT
Release Date Price:
MXN17.8
(+11.25%)
Jonathan Aschoff
ROTH Capital Partners, LLC - Analyst
I'm Jonathan Aschoff, senior biotechnology analyst at ROTH MKM; and with us now is Shankar Musunuri, the CEO of Ocugen. And hello, Shankar. Welcome.
Shankar Musunuri
Ocugen, Inc. - Chairman of the Board, CEO, & Co-Founder
Thank you. Thank you, Jonathan. Thank you for having me.
Questions & Answers
Jonathan Aschoff
ROTH Capital Partners, LLC - Analyst
It's great to have you. So your company has had a diversified portfolio, gene therapy, cell therapy, biologics, vaccine. You're running the whole gamut here. How did that happen, and what are some unifying characteristics you can tell us that have led to that?
Shankar Musunuri
Ocugen, Inc. - Chairman of the Board, CEO, & Co-Founder
Yeah. You have, starting with the shared science, you take gene therapies and vaccines with their novel vectors, there are a lot of commonalities. And there is also manufacturing change platform with a lot of similarities.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot